Zusammenfassung:
Hintergrund: Die kombinierte alternierende Chemo-Strahlentherapie des SCLC im Stadium III wird im Rahmen einer prospektiven Studie untersucht und im Rahmen der vorhandenen Literatur diskutiert. Methode: Geprüft wird ein alternierendes Regime von Chemotherapie (Carboplatin: AUC5, Etoposid: 3 × 120 mg/m2 , Vincristin: 2 mg d1, WH d 28) und Strahlentherapie (1 × 4 Gy/Woche) an 32 Patienten im Stadium IIIa und IIIb. Ergebnisse: Die kombinierte Strahlentherapie wird mit geringer Toxizität toleriert, wobei dosislimitierend die Hämatotoxizität war. Die Ergebnisse sind gut mit einem Response von 75 %, einem medianen Überleben von 14,5 Monaten und einem 2-Jahres-Überleben von 34 %. Zur Zeit werden 5 Langzeitüberlebende (über 29 Monate) beobachtet. Sowohl Lokal- als auch Fernrezidive treten in gleicher Häufigkeit (je 34 %) auf. Schlußfolgerungen: Die kombinierte Strahlen-Chemotherapie beim SCLC im Stadium III ist mit dem hier geprüften Regime gut praktikabel. Sie verspricht eine hohe Ansprechrate und ein günstiges 2-Jahres-Überleben. Lokal- und Fernrezidive treten in gleicher Häufigkeit auf und unterstreichen die Notwendigkeit sowohl einer besseren lokalen als auch systemischen Kontrolle.
Background: The combination of radio-chemotherapy is accepted standard in limited-disease small cell lung cancer, but the best way of combining the two modalities is still unknown. To test an alternating regime of early radiotherapy with hypofractionated radiotherapy we performed a phase II study in stage III small cell lung cancer. Method: 32 SCLC patients (n = 7 IIIa, n = 25 IIIb) were treated with a weekly alternating regime with either chemotherapy or radiotherapy. Chemotherapy included carboplatin (AUC5), etoposide (3 × 120 mg/m2 ) and vincristine (2 mg), repeated on day 28 for six cycles. Radiotherapy started one week before chemotherapy and was applied weekly 1 × 4 Gy, using a split-course regimen. Results: Combined radio-chemotherapy was well tolerated with dose-limiting hemotoxicity and very few cases of oesophagitis. Overall response was 75 %, median survival 14.5 months and the 2-year survival was 34.4 %. 5 patients are still living now for more than 29 months. Treatment failure was local and systemic in 34 % of the patients. Systemic failure included 6 patients with brain metastases. Conclusion: Combined radio-therapy in small-cell lung cancer using an alternating hypofractionated regimen is well tolerated. Response rate and 2-year survival are promising. Local and systemic failure is an ongoing problem and requires better local and systemic control of the disease.
Literatur
1
Bonner J A, Sloan J A, Hillman S H. et al .
A quality-adjusted re-analysis of a phase III trial comparing once-daily thoracic radiation therapy versus twice-daily thoracic radiation therapy in patients with limited stage small cell lung cancer.
Proc ASCO.
1999;
18
1799
2
Bunn P A, Lichter A S, Makuch R W. et al .
Chemotherapy alone or chemotherapy with chest radiotherapy in limited stage small cell lung cancer.
Ann Intern Med.
1987;
106
655-662
3
Bunn P A, Crowley J, Kelly K. et al .
Chemoradiotherapy with or without GM-CSF in the treatment of limited stage small cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
JCO.
1995;
13,/
1632-1641
4
Choi N C, Carey R W.
Importance of radiation dose in achieving improved locoregional tumor control in limited-stage small-cell lung carcinoma.
Int J Radiat Oncol Biol Phys.
1989;
17
307-310
5
Coy P, Hodson I, Payne D G. et al .
The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer: inital results of a Canadian multicenter randomized trial.
Int J Radiat Oncol biol Phys.
1988;
14
219-226
6
Gatzemeier U, Hossfeld D K, Neuhauss R. et al .
Phase II and III studies with carboplatin in small cell lung cancer.
Semin Oncol.
1992;
19 S 2
28-36
7
Goodman G E, Crowley J J, Blasko J C. et al .
Treatment of limited small cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin and cyclophosphamide and chest radiotherapy: A Southwest Oncology Group Study.
JCO.
1990;
8, 1
39-47
8
Goto K, Nishiwaki Y, Takada M. et al .
Final results of a phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited stage small cell lung cancer (LD-SCLC): The Japan clinical oncology group (JCOG).
Proc ASCO.
1999;
18
1805
9
Gregor A, Drings P, Burghouts J. et al .
Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited disease patients with SCLC: A EORTC study.
JCO.
1997;
15(8)
2840-2849
10
Gregor A, Cull A, Stephens R J. et al .
Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentric randomised trial.
Eur J Canc.
1997;
33,11
1752-1758
11
Gridelli C, D'Aprile M, Curcio C. et al .
Carboplatin plus epirubicin plus VP-16, concurrent “split course” radiotherapy and adjuvant surgery for limited small cell lung cancer.
Lung Cancer.
1994;
11
83-91
12
Ihde D, Souhami B, Comis R. et al .
Consensus report small cell lung cancer.
Lung Cancer.
1997;
17 S
S19-S21
13
Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S.
Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study.
JCO.
1997;
15; 3
893-900
14
Jeremic B, Shibamoto Y, Acimovic L, Milisavlevis S.
Carboplatin, Etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma.
Cancer.
1998;
82; 5
836-841
15
Johnson D H, Bass D, Einhorn L H. et al .
Combination chemotherapy with or without thoracic radiotherapy in limited-stage small cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
JCO.
1993;
11, 7
1223-1229
16
Johnson B E, Bridges J D, Sobczeck M. et al .
Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin and vincristine.
J Clin Oncol.
1996;
14
806-813
17
Koch K, Broll I, Cordes G. et al .
Strahlentherapie der Bronchialkarzinome.
Atemw.-Lungenkrankheiten.
1987;
13, 3
81-87
18
Kosmidis P A, Samantas E, Fountzilas G. et al .
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study.
Semin Oncol.
1994;
21 S3
23-30
19
Kristjansen P EG, Hansen H H.
Prophylactic cranial irradiation in small cell lung cancer - an update.
Lung cancer.
1995;
12, S3
S23-S40
20
Kubota K, Itoh R, Kodama T. et al .
Concurrent cisplatin/etoposide (PE) and twice-daily thoracic radiotherapy (BID TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited-stage small cell lung cancer.
Proc ASCO.
1999;
18
1978
21 Maurer L H, Herndon J E, Hollis D R. et al .Randomized trial of chemotherapy and radiation therapy with or without Warfarin for limited-stage small cell lung cancer: a Cancer and Leukemia Group B study .
22
Meropol J J, Miller L L, Korn E L.
Severe myelosuppression resulting from concurrent administration of granulocyte colony stimulating factor and cytotoxic chemotherapy.
J Natl Cancer Inst.
1992;
84
1201-1202
23
Miller A B, Hoogsstraten B, Staquet M, Winkler A.
Reporting results of cancer treatment.
Cancer.
1981;
47
207-214
24
Murray N, Coy P C, Pater J L. et al .
Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer.
JCO.
1993;
11; 2
336-344
25 National Cancer Institute: NCI .Investigator's Handbook. A manual for participants in clinical trials of investigational agents. Cancer therapy evaluation program. Division of cancer treatment, National Cancer Institute, Bethesda . Maryland (USA); 1993
26
Perry M C, Eaton W L, Propert K J. et al .
Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung.
N Engl J Med.
1987;
3316
912-918
27
Pignon J P, Arriagada R, Idhe D C. et al .
A meta-analysis of thoracic radiotherapy for SCLC.
NEJM.
1992;
327, 23
1618-1624
28
Salazar O M, Slawson R G, Pouissin-Rosillo H. et al .
A prospective randomized trial comparing once-a-week vs. daily radiation therapy for locally-advanced non-metastatic lung cancer.
Int J Rad Oncol Biol Phys.
1986;
12
779-787
29
Serke M, Lienert T, Bender J. et al .
Lung cancer: Clinical data from a 10 years registry.
ERJ.
1998;
12, 307S
P2045
30
Turrisi A, Kyungmann K, Blum R B. et al .
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
NEJM.
1999;
340, 4
265-271
31
Warde P, Payne D.
Does thoracic radiation improve survival and local control in limited-stage small cell carcinoma of the lung.
J Clin Oncol.
1992;
10
890-895
32
Work E, Nielsen O S, Bentzen S. et al .
Randomized study of initial versus late chest irradiation combined with chemotherapy in limited stage small cell lung cancer.
JCO.
1997;
15, 9
3030-3037
1 Teile dieser Arbeit wurden als Vortrag auf der Jahrestagung der DGP in Bad Reichenhall 1999 vorgestellt.
Dr. med. Monika Serke
Lungenklinik Heckeshorn, Pneumologie II
Zum Heckeshorn 33
14109 Berlin